De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Issue 2 (28th January 2020)

• Record Type: Journal Article
• Authors: Hu, Bei; Nastoupil, Loretta J.; Loghavi, Sanam; Westin, Jason R.; Thakral, Beenu; Fayad, Luis E.; Hagemeister, Fredrick; Neelapu, Sattva; Samaniego, Felipe; Lee, Hun J.; Wang, Michael L.; Fanale, Michelle; Fowler, Nathan; Oki, Yasuhiro
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 2(2020)
• Page Start: 328
• Page End: 336
• Publication Date: 2020-01-28
• Subjects: CD5+ DLBCL -- extranodal disease -- CNS relapse -- retrospective review; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2019.1663418
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: CD5+ diffuse large B-cell lymphoma (DLBCL), NOS represents a distinct subset of DLBCL associated with poorer outcomes and extranodal disease. We analyzed characteristics and outcomes for 102 CD5+ DLBCL patients diagnosed between 2001-2016. The majority had poor-risk disease based on R-IPI scores; 80% had extranodal disease at diagnosis. CNS relapse occurred 23% of the time. Median PFS and OS was 18.9 months and 112 months, respectively. Four-year PFS rates were 100%, 53%, and 41% for patients with R-IPI scores of very good, good, and poor, respectively. CD5+ DLBCL represents a subset of patients with poor outcomes despite rituximab and anthracycline-based regimens. There is a need for novel therapies and clinical trials for this high-risk group of patients. Given high rates of CNS relapse, better CNS prophylaxis with frontline therapy requires more study.